Trends in Psychiatry and Psychotherapy
https://trends.org.br/article/doi/10.1590/S2237-60892013000300002
Trends in Psychiatry and Psychotherapy
Trend

Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations

Antipsicóticos atípicos no tratamento da agressividade patológica em crianças e adolescentes: revisão da literatura e recomendações clínicas

Eduardo Henrique Teixeira; Antonio Jacintho; Heloisa Valler Celeri; Paulo Dalgalarrondo

http://dx.doi.org/10.1590/S2237-60892013000300002 Trends Psychiatry Psychother, vol.35, n3, p.151-159, 2013
PDF
SciELO
Downloads: 0
Views: 621

Abstract

Objective: To review the literature about the use of atypical antipsychotics in the treatment of pathological aggression in children and adolescents. Method: The databases MEDLINE, SciELO, and LILACS were searched for publications in Portuguese or English from 1992 to August 2011 using the following keywords: mental disease, child, adolescent, treatment, atypical antipsychotic, aggressive behavior, aggression, and violent behavior. Results: Sixty-seven studies of good methodological quality and clinical interest and relevance were identified. Studies including children and adolescents were relatively limited, because few atypical antipsychotics have been approved by the Food and Drug Administration (FDA). All the medications included in this review (risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole and clozapine) have some effectiveness in treating aggression in children and adolescents, and choices should be based on clinical indications and side effects. Conclusions: There are few studies about the effectiveness and safety of atypical antipsychotics for the pediatric population, and further randomized controlled studies with larger groups of patients and more diagnostic categories, such as severe conduct disorder and oppositional defiant disorder, should be conducted to confirm the results reported up to date and to evaluate the impact of long-term use.

Keywords

Aggression, violence, atypical antipsychotics, behavioral disorders, children, adolescents

Resumo

Objetivo: Realizar uma revisão sistemática da literatura científica sobre o uso de antipsicóticos atípicos (APAs) no tratamento da agressividade patológica em crianças e adolescentes. Método: Foi realizada busca eletrônica nas bases de dados MEDLINE, SciELO e LILACS, de 1992 a agosto 2011, considerando artigos publicados em língua inglesa e portuguesa. Foram utilizadas associações das seguintes expressões: mental disease, child, adolescent, treatment, atypical antipsychotic, aggressive behaviour, aggression e violent behavior. Resultados: Foram identificados 67 artigos de boa qualidade metodológica, de relevância e interesse clínico para o tema em foco. De modo geral, os estudos são relativamente limitados para esta faixa etária, resultado do fato de poucos APAs terem sido aprovados pela Food and Drug Administration (FDA). Dentre as medicações consideradas nesta revisão (risperidona, olanzapina, quetiapina, ziprazidona, aripiprazol e clozapina), todas elas podem ter alguma efetividade no tratamento da agressividade em crianças e adolescentes, ficando a escolha baseada na indicação clínica e perfil de efeitos colaterais. Conclusão: O número ainda limitado de estudos acerca da efetividade e segurança na população pediátrica demanda pesquisas futuras com grupos maiores de pacientes e com mais categorias diagnósticas (como, por exemplo, as formas graves de transtorno de conduta e transtorno desafiador de oposição), desenhadas de forma randomizada e controlada. Assim poderão ser confirmados os achados até o momento e o impacto do uso em longo prazo.

Palavras-chave

Agressão, violência, agentes antipsicóticos, transtornos do comportamento, infância, adolescência

References

Schur SB, Sikich L, Findling RL, Malone RP, Crismon ML, Derivan A. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY): Part I: a review. J Am Acad Child Adolesc Psychiatry. 2003;42:132-144.

Prado-Lima PA. Pharmacological treatment of impulsivity and aggressive behavior. Rev Bras Psiquiatr. 2009;31(^s2):S58-65.

Garland AF, Hough RL, McCabe KM, Yeh M, Wood PA, Aarons GA. Prevalence of psychiatric disorders in youths across five sectors of care. J Am Acad Child Adolesc Psychiatry. 2001;40:409-18.

Jensen PS, Youngstrom EA, Steiner H, Findling RL, Meyer RE, Malone RP. Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: implications for medication studies. J Am Acad Child Adolesc Psychiatry. 2007;46:309-22.

Siever LJ. Neurobiology of aggression and violence. Am J Psychiatry. 2008;165:429-42.

Siegel A, Bhatt S, Bhatt R, Zalcman SS. The neurobiological bases for development of pharmacological treatments of aggressive disorders. Curr Neuropharmacol. 2007;5:135-47.

Bordin IA, Offord DR. Transtorno de conduta e comportamento anti-social. Rev Bras Psiquiatr. 2000;22(^sII):12-15.

Mendes DD, Mari Jde J, Singer M, Barros GM, Mello AF. Study review of biological, social and environmental factors associated with aggressive behavior. Rev Bras Psiquiatr. 2009;31(^s2):S77-85.

Nestor PG. Neuropsychological and clinical correlates of murder and other forms of extreme violence in a forensic psychiatric population. J Nerv Ment Dis. 1992;180:418-23.

Bernstein DP, Cohen P, Skodol A, Bezirganian S, Brook JS. Childhood antecedents of adolescent personality disorders. Am J Psychiatry. 1996;153:907-13.

Blair RJ, Peschardt KS, Budhani S, Mitchell DG, Pine DS. The development of psychopathy. J Child Psychol Psychiatry. 2006;47:262-76.

Soller MV, Karnik NS, Steiner H. Psychopharmacologic treatment in juvenile offenders. Child Adolesc Psychiatr Clin N Am. 2006;15:477-99.

Pappadopulos E, Macintyre Ii JC, Crismon ML, Findling RL, Malone RP, Derivan A. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY): Part II. J Am Acad Child Adolesc Psychiatry. 2003;42:145-61.

James AC. Prescribing antipsychotics for children and adolescents. Adv Psychiatr Treat. 2010;16:63-75.

Cohen SA, Underwood MT. The use of clozapine in a mentally retarded and aggressive population. J Clin Psychiatry. 1994;55:440-44.

Jensen PS. The role of psychosocial therapies in managing aggression in children and adolescents. J Clin Psychiatry. 2008;69(^s4):37-42.

Rutter M, Taylor EA. Child and Adolescent Psychiatry. 2002.

Connor DF, Glatt SJ, Lopez ID, Jackson D, Melloni Jr RH. Psychopharmacology and aggression: I: a meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry. 2002;41:253-61.

Heyneman EK. The aggressive child. Child Adolesc Psychiatr Clin N Am. 2003;12:667-77.

Brasil HH, Belisário Filho JF. Psicofarmacoterapia. Rev Bras Psiquiatr. 2000;22(^sII):42-7.

Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63:679-85.

Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry. 2008;69(^s4):9-14.

Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry. 1997;36:835-43.

Toren P, Laor N, Weizman A. Use of atypical neuroleptics in child and adolescent psychiatry. J Clin Psychiatry. 1998;59:644-56.

Gilberg C. Typical neuroleptics in chil and adolescent psychiatry. Eur Child Adolesc Psychiatry. 2000;9(^sI):2-8.

Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.

Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47:9-20.

Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008;69(^s4):26-36.

Correll CU, Penzner JB, Parikh UH, Mughal T, Javed T, Carbon M. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2006;15:177-206.

Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC. Childhood-onset schizophrenia: A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996;53:1090-7.

Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006;63:721-30.

Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol. 1999;9:239-45.

Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002;159:1337-46.

Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry. 2000;39:509-16.

Dunbar F, Kusumakar V, Daneman D, Schulz M. Growth and sexual maturation during long-term treatment with risperidone. Am J Psychiatry. 2004;161:918-20.

Lemmon ME, Gregas M, Jeste SS. Risperidone use in autism spectrum disorders: a retrospective review of a clinic-referred patient population. J Child Neurol. 2011;26:428-32.

McDougle CJ, Stigler KA, Erickson CA, Posey DJ. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry. 2008;69(^s4):15-20.

McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314-21.

Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114:e634-41.

Eberhard J, Lindström E, Holstad M, Levander S. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand. 2007;115:268-76.

Handen BL, Hardan AY. Open-label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavioral disorders. J Am Acad Child Adolesc Psychiatry. 2006;45:928-35.

Masi G, Milone A, Canepa G, Millepiedi S, Mucci M, Muratori F. Olanzapine treatment in adolescents with severe conduct disorder. Eur Psychiatry. 2006;21:51-7.

Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol. 1999;19:37-44.

Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry. 2001;40:887-94.

Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl). 2001;155:128-34.

Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001;21:389-97.

Findling RL, Reed MD, O'Riordan MA , Demeter CA, Stansbrey RJ, McNamara NK. Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:792-800.

Findling RL, Reed MD, O'Riordan MA, Demeter CA, Stansbrey RJ, McNamara NK. A 26-week open-label study of quetiapine in children with conduct disorder. J Child Adolesc Psychopharmacol. 2007;17:1-9.

Kronenberger WG, Giauque AL, Lafata DE, Bohnstedt BN, Maxey LE, Dunn DW. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol. 2007;17:334-47.

Martin A, Koenig K, Scahill L, Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 1999;9:99-107.

Findling RL, McNamara NK, Gracious BL, O'Riordan MA , Reed MD, Demeter C. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol. 2004;14:287-94.

McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry. 2002;41:921-7.

Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004;14:455-63.

Valicenti-McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol. 2006;16:549-60.

Kranzler H, Roofeh D, Gerbino-Rosen G, Dombrowski C, McMeniman M, DeThomas C. Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2005;44:55-63.

Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C. Clinical effects of clozapine on autistic disorder. Am J Psychiatry. 1996;153:738.

Chen NC, Bedair HS, McKay B, Bowers Jr MB, Mazure C. Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry. 2001;62:479-80.

Gogtay N, Rapoport J. Clozapine use in children and adolescents. Expert Opin Pharmacother. 2008;9:459-65.

Gerbino-Rosen G, Roofeh D, Tompkins DA, Feryo D, Nusser L, Kranzler H. Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry. 2005;44:1024-31.

Pappadopulos EA, Siennick SE, Jensen PS. Antipsychotics for aggressive adolescents: barriers to best practice. Expert Rev Neurother. 2003;3:85-98.

Findling RL, Frazier JA, Gerbino-Rosen G, Kranzler HN, Kumra S, Kratochvil CJ. Is there a role for clozapine in the treatment of children and adolescents. J Am Acad Child Adolesc Psychiatry. 2007;46:423-8.

Gobbi G, Pulvirenti L. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour. J Psychiatry Neurosci. 2001;26:340-1.

Kraus JE, Sheitman BB. Clozapine reduces violent behavior in heterogeneous diagnostic groups. J Neuropsychiatry Clin Neurosci. 2005;17:36-44.

Smith H, White T. The effect of clozapine on the social behaviour schedule in patients attending a forensic psychiatry day hospital. Med Sci Law. 2004;44:213-6.

Sikich L. Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders. J Clin Psychiatry. 2008;69(^s4):21-5.

Correll CU. Metabolic side effects of second-generation antipsychotics in children and adolescents: a different story?. J Clin Psychiatry. 2005;66:1331-2.

Stigler KA, McDougle CJ. Pharmacotherapy of irritability in pervasive developmental disorders. Child Adolesc Psychiatr Clin N Am. 2008;17:739-52.

616b229ba9539533dd167df2 trends Articles
Links & Downloads
2238-0019 (Electronic)
Trends Psychiatry Psychother ©2024 All rights reserved.

Trends Psychiatry Psychother

Share this page
Page Sections